Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cybin Inc (NY: CYBN ) 0.2660 -0.0006 (-0.23%) Official Closing Price Updated: 8:00 PM EDT, Aug 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Cybin Inc < Previous 1 2 3 4 5 6 7 8 9 ... 37 38 Next > Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted October 22, 2023 Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts Via Benzinga Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business October 20, 2023 Small Pharma Inc. (OTCQB: DMTTF), the short-acting psychedelics biotech about to be purchased by Cybin Inc. Via Benzinga Moving Closer To Cybin Acquisition, Small Pharma Obtains Final Order Approving Arrangement October 18, 2023 Short-acting psychedelics biotech Small Pharma Inc. Via Benzinga Small Pharma Obtains Final Order Approving Arrangement October 17, 2023 From Cybin Inc. Via Business Wire Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More October 16, 2023 Cybin And Small Pharma Shareholders Green Light Acquisition Resolution Via Benzinga Exposures Product Safety Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates October 13, 2023 Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc. Via Benzinga InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Reports on Voting Results from Annual Shareholder Meeting October 13, 2023 Via Investor Brand Network Cybin Announces Results of Annual and Special Meeting of Shareholders October 12, 2023 From Cybin Inc. Via Business Wire Psyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & More October 06, 2023 Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares Via Benzinga InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Abstract Selected for Presentation at Sixth Annual Neuropsychiatric Drug Development Summit October 06, 2023 Via Investor Brand Network Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit October 06, 2023 From Cybin Inc. Via Business Wire InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Present at Jefferies Inaugural Biotech CNS/Neuro Summit October 04, 2023 Via Investor Brand Network Cybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summit October 04, 2023 From Cybin Inc. Via Business Wire Cybin Completes Dosing In Phase 2 Study Of CYB003 For Major Depressive Disorder Treatment October 03, 2023 Cybin Inc. (NYSE: CYBN), a clinical-stage biotech company developing novel psychedelic-based mental health treatments, has completed dosing of the final participant cohort in the Via Benzinga Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares October 03, 2023 NY Mets owner billionaire Steve Cohen has bought as many as 119,092,680 ordinary shares of clinical-stage biopharmaceutical company Bionomics Limited (NASDAQ: BNOX) through his Point72 asset management... Via Benzinga InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Wraps Up Phase 2 Study Dosing for Final Cohort October 03, 2023 Via Investor Brand Network Cybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorder October 03, 2023 From Cybin Inc. Via Business Wire Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More October 02, 2023 Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of... Via Benzinga InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Positive Top-Line Data Gathered from Small Pharma Study September 27, 2023 Via Investor Brand Network Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder September 27, 2023 From Cybin Inc. Via Business Wire Cybin And Fluence Partner To Support EMBARK Training For Phase 3 CYB003 Trial For Depression September 26, 2023 Clinical-stage psychedelics biotech Cybin Inc. Via Benzinga Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results September 26, 2023 New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out. Via Benzinga Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More September 26, 2023 Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge Via Benzinga Topics Economy Exposures Interest Rates Cybin Announces Agreement with Fluence to Support Scaling of EMBARK Training for CYB003 Phase 3 Trial September 26, 2023 From Cybin Inc. Via Business Wire InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Cantor Global Healthcare Conference September 25, 2023 Via Investor Brand Network Cybin to Participate in the Cantor Global Healthcare Conference September 25, 2023 From Cybin Inc. Via Business Wire InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Schedules Annual Shareholder Meeting September 22, 2023 Via Investor Brand Network Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression September 21, 2023 Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive... Via Benzinga Cybin Announces Date of Annual and Special Meeting of Shareholders September 21, 2023 From Cybin Inc. Via Business Wire InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Enrollment in Phase 2 CYB003 Study September 21, 2023 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property < Previous 1 2 3 4 5 6 7 8 9 ... 37 38 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.